Transcarent

Active#3 worldwide · Telemedicine

Telemedicine

HQUnited States

Last roundPreferred equity · Jan 2025

Uback rankings

Ranking	Tier	Rank	Edition	Next update
Telemedicine · worldwide	Top 10	#3	Edition 0 (beta) · Sep 2026	2 Jan 2027

Rank historySep 2026 · #3 TelemedicineFirst edition: no movements yet.

Estimated valuation

AI · Telemedicine ranking (worldwide)

≈ USD 2.8bnUSD 1.9–4.2bn · Unicorn Medium confidence

Hundreds of k$

Millions $

Tens of M$

Hundreds of M$

Unicorn

Decacorn

Anchor: Last known equity round: Preferred equity · amount not disclosed (preferred stock financing the Accolade deal) · Jan 2025
Published valuation: USD 2.2bn · May 2024 · older than 24 months, shown for reference

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Funding history

Date	Round	Amount	Type	Investors	Source
Jan 2025	Preferred equity	amount not disclosed (preferred stock financing the Accolade deal)	Equity	General Catalyst, 62 Ventures	mobihealthnews.com

Rounds as cited by Uback’s rankings and their sources. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Transcarent as a PDF, on one of three angles only:

ValuationWhat is Transcarent worth?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication and never change the rank.

Invest

Transcarent is not open to Backers. A company opens only when a shareholder plans to sell or the company plans to raise.

Back the market instead: your intention joins a pool, passed to the local partner once it reaches critical mass.

Declare an interest in telemedicine Name Transcarent as a preferred company (measures demand, promises nothing)

Telemedicine poolBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until its pool is passed on. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run Transcarent?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round. Claiming never changes the rank.

Claim this profile Report an upcoming round →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Press & investor announcements2 sources

Read by the AI at the next edition.

Comparable companies in telemedicine

Full telemedicine ranking →

Sword Health#2United StatesUnicorn eMed#4United StatesUnicorn Ro#1United StatesUnicorn Included Health#5United StatesUnicorn

Investors in Transcarent: General Catalyst · 62 Ventures

Sources. mobihealthnews.com · fiercehealthcare.com

Last updated: Sep 2026Report an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.